Epidermal growth factor receptor inhibitor-related skin toxicity: Mechanisms, treatment, and its potential role as a predictive marker

Clinical Colorectal Cancer

Volumn 7, Issue 1, 2008, Pages 33-43

  Bianchini, Diletta ^a   Jayanth, Akali ^a   Yu, Jo Chua ^a   Cunningham, David ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cetuximab; Panitumumab; Rash; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETAMETHASONE VALERATE; CETIRIZINE; CETUXIMAB; CISPLATIN; CLINDAMYCIN; DUODERM; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUCLOXACILLIN; GEFITINIB; GEMCITABINE; HYDROXYZINE; IRINOTECAN; ISOTRETINOIN; LAPATINIB; LORATADINE; LYMECYCLINE; MINOCYCLINE; MONOCLONAL ANTIBODY; PANITUMUMAB; PREGABALIN; PROTEIN TYROSINE KINASE INHIBITOR; SILVER NITRATE; SUCRALFATE; TAZAROTENE; TETRACYCLINE; UNINDEXED DRUG;

ACNE; CLINICAL TRIAL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; HAIR DISEASE; HAIR GROWTH; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MONOTHERAPY; OUTCOME ASSESSMENT; PARONYCHIA; PATHOPHYSIOLOGY; PROGNOSIS; PYOGENIC GRANULOMA; RASH; REVIEW; SIDE EFFECT; SKIN ABSCESS; SKIN DEFECT; SKIN FISSURE; SKIN FRAGILITY; SKIN MANIFESTATION; SKIN TOXICITY; SOCIAL PSYCHOLOGY; TELANGIECTASIA; XEROSIS;

EID: 39149117695     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.005     Document Type: Review

References (97)

1. Di Marco E, Albanese E, Benso S, et al. Expression of epidermal growth factor receptor and transforming growth factor alpha in human larynx carcinoma. Cancer Lett 1992; 65:189-99.
2. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
3. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376:337-41.
4. Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77:25-79.
5. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410:83-6.
6. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-25.
7. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-8.
8. Castillo L, Etienne-Grimaldi MC, Fischel JL. Pharmacological background of EGFR targeting. Ann Oncol 2004; 15:1007-12.
9. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-70.
10. Nicholson RI, Gee GM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4):S9-15.
11. Ciardiello F. An update of new targets for cancer treatment: receptor-mediated signals. Ann Oncol 2002; 13(suppl 4):29-38.
12. Mayer A, Takimoto M, Fritz E. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-60.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
14. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination-with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-84.
15. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-94.
16. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
17. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
18. Mendelsohn J, Baselga J. Status of epidermal growth factor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
19. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-5.
20. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302.
21. Ciardiello F, Bianco R, Damiano V. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-47.
22. Saltz L, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
23. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
24. Hecht JR, Patnaik A, Malik I. ABX-EGF monotherapy in patients with metastatic colorectal cancer (mCRC): an update analysis. J Clin Oncol 2004; 22:248 (Abstract 3511).
25. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5:2884-90.
26. Atasoy BM, Bentzen SM, Trott KR. The epidermal growth factor receptor is involved in accelerated repopulation in squamous cell carcinoma of the head and neck. Exp Strahlenther Klin Strahlenbiol 2004; 13:39-41.
27. Sartor CI. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 2004; 1:80-7.
28. Bonner JA, Harari PM, Giralt JL. Radiotherapy plus Cetuximab for Squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78.
29. Hofheinz RD, Horisberger K, Woernle C, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:1384-90.
30. Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18:738-44.
31. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-33.
32. Folprecht G, Lutz M, Schoeffski P, et al. Cetuximab/irinotecan/high-dose- 5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Presented at: the American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, California. Abstract 283.
33. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-76.
34. Molinari E, De Quatrebarbes J, André T. Cetuximab-induced acne. Dermatology 2005; 211:330-3.
35. Boucher KW, Davidson K, Mirkhur B, et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 45:632-3.
36. Bouche O, Brixi-Brenmasour H, Bertin A. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16:1711-2.
37. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79.
38. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-50.
39. Foon KA, Yang X, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984-90.
40. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-14.
41. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-302.
42. Rowinsky EK, Schwartz GH, Jared A, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-15.
43. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601.
44. Sherertz EF. Acneiform eruption due to "megadose" vitamins B6 and B12. Cutis 1991; 48:119-20.
45. Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003; 21:2237-46.
46. Tewes M, Schleucher N, Dirsch O, et al. Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. Proc Am Soc Clin Oncol 2001; 20:95a (Abstract 378).
47. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-43.
48. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-58.
49. Saltz L, Rubin MS, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Clin Cancer Res 2001; 7:3766s.
50. De Bono JS, Schwartz G, Monroe P, et al. Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK) , administered in combination with capecitabine. Proc Am Soc Clin Oncol 2003; 22:56 (Abstract 225).
51. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138:129-31.
52. Herbst RS, LoRusso PM, Purdom M, et al. Dermatological side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4:366-9.
53. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3:599-606.
54. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23:165-74.
55. Chang CG, Yang TY, Chen KC. Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:4646-8.
56. Roé E, García Muret MP, Marcuello E, et al Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429-37.
57. Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet 2002; 3:199-209.
58. Nanney LB, Stoscheck CM, King LE. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94:742-8.
59. Peud D, Hamacher L, Pittelkow. MR EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997; 109:751-6.
60. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2001; 20:110-24.
61. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478-86.
62. Woodworth CD, Michael E, Marker, et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005; 4:650-8.
63. Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110(pt 2):113-21.
64. Mascia M, Mariani V, Girolami G, et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163:303-12.
65. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-12.
66. Murillas R, Larcher F, Conti CJ, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216-23.
67. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:29-31.
68. Heck DE, Laskin DL, Gardner CR, et al. Epidermal growth factor suppresses nitric oxide and hydrogen peroxide production by keratinocytes. Potential role for nitric oxide in the regulation of wound healing. J Biol Chem 1992; 267:21277-80.
69. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
70. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10:701-9.
71. Defize LH, Boonstra J, Meisenhelder J, et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989; 109:2495-507.
72. Clark GM, Zborowski DM, Culbertson JL, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006; 1:837-46.
73. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab pluschemotherapy. Br J Cancer 2007; 96:1166-9.
74. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5.
75. Finocchiaro G, Cappuzzo F, Jänne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 2007; 25(18 suppl):168s (Abstract 4021).
76. Amado RG, Wolf M, Freeman D, et al. Wild-type K-RAS is required for Panitumumab efficacy in patients with mCRC: results from a randomized, controlled trial. Presented at: the 14th Biannual European Cancer Conference; September 23-27, 2007; Barcelona, Spain. Abstract 7.
77. Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005; 18:1350-6.
78. Sauer T, Guren MG, Noren T, et al. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology 2005; 47:560-4.
79. Barber TD, Vogelstein B, Kinzler KV, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351:2883.
80. Xiong HQ, Rosenberg A, Lo Buglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22:2610-6.
81. Gebhardt F, Burger H, Brandt B, et al. Modulation of EGFR gene transcription by a polymorphic repetitive sequence - a link between genetics and epigenetics. Int J Biol Markers 2000; 15:105-10.
82. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006; 1:406-12.
83. Perea S, Oppenheimer D, Amador M, et al. Genotypic bases of EGFR inhibitors pharmacological actions. J Clin Oncol 2004; 22(14 suppl):196 (Abstract 3005).
84. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21.
85. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-87.
86. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-7.
87. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22:51 (Abstract 204).
88. Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small-cell lung cancer. Ann Oncol 2005; 16:780-5.
89. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-46.
90. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
91. Tejpar S, Peeters M, Humblet Y, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST). Pharmacokinetic and efficacy data of a randomized study. J Clin Oncol 2007; 25(18 suppl):172s (Abstract 4037).
92. Erbitux SmPC, April 2007.
93. Agero AL, Scope A, Myskowski P, et al. Prophylaxis with systemic minocycline and topical tazarotene (a retinoid) for the cetuximab associated acne-like eruption. Presented at: the 2007 American Academy of Dermatology Annual Meeting; February 2-6, 2007; Washington, DC. Abstract P508.
94. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25:133-5.
95. Jatoi A, Rowland K, Sloan JA, et al. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? a phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol 2007; 25(18 suppl):494s (Abstract LBA9006).
96. Porzio G, Aielli F, Verna L, et al Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006; 32:397-8.
97. Di Giovanna. Systemic retinoid therapy. Dermatol Clin 2001; 19:161-7.